Heather Lupole
Nurse Practitioner · Millersburg, PANPI 1770081291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,433, 3.9 times the $366 reported in 2021. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$792
- Lilly USA, LLC$689
- Novo Nordisk$597
- AstraZeneca$261
- Pfizer$247
- Abbott$180
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,083100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $792 |
| Lilly USA, LLC | 47 | $689 |
| Novo Nordisk | 38 | $597 |
| AstraZeneca | 14 | $261 |
| Pfizer | 15 | $247 |
| Abbott | 9 | $180 |
| GSK | 9 | $152 |
| Dexcom, Inc. | 6 | $127 |
| Teva Pharmaceuticals USA, Inc. | 5 | $103 |
| Boehringer Ingelheim | 6 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $100 |
| E.r. Squibb & Sons, L.L.C. | 4 | $85 |
| Cequr Corporation | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Exact Sciences | 3 | $63 |
| Smith+Nephew | 2 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Alkermes, Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $39 |
| Novartis | 2 | $33 |
| Merck | 2 | $31 |
| Viiv Healthcare Company | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Amgen | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
How this compares
$4,094 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 48 | $90,411 |
| EliquisApixaban | 65 | $80,440 |
| OzempicSemaglutide | 39 | $65,761 |
| JardianceEmpagliflozin | 28 | $45,908 |
| MounjaroTirzepatide | 31 | $42,091 |
| XareltoRivaroxaban | 19 | $32,534 |
| FarxigaDapagliflozin Propanediol | 34 | $31,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,893 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $13,834 |
| RybelsusSemaglutide | 13 | $11,927 |
| MyrbetriqMirabegron | 12 | $10,299 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,556 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $4,736 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $4,581 |
| Atorvastatin Calcium | 292 | $3,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $689 | $132,50279 claims |
| PfizerEliquis | $247 | $80,44065 claims |
| Novo NordiskOzempic, Rybelsus | $597 | $77,68852 claims |
| Boehringer IngelheimJardiance | $103 | $45,90828 claims |
| AstraZenecaFarxiga | $261 | $31,24734 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $152 | $21,44935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Millersburg
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.